Fig. 2: HM EV surface marker characterization.

a Clustering of term and preterm HM EVs using principal component analysis (n = 7), negative control, and capture beads only control (n = 2). b Following background normalization, HM EVs expressed surface markers ROR1, HLA-DR,DP,DQ, HLA-ABC, CD326, CD146, CD133/1, CD105, CD86, CD45, CD44, CD40, CD29, CD24, CD14, and CD4, in addition to canonical EV markers CD9, 63 and 81. n = 2–7, *p < 0.04, Welch’s t-test.